AstraZeneca and insitro partner on AI-enabled target discovery

AstraZeneca and insitro will combine AI with human and cellular data to prioritize targets for MASH and cardiomyopathies; insitro is to advance selected programs to candidate stage, with AstraZeneca holding worldwide rights. The deal’s milestone structure signals commercial confidence, not proof of therapeutic success; target validation and eventual clinical outcomes remain to be seen.